CD58 and acute lymphoblastic leukemia: More importantly, CD58 has high accuracy and stability in minimum residual disease (MRD) detection at different clinical stages, thus CD58 could be used as an effective indicator for monitoring MRD in B-cell progenitor ALL (BCP-ALL) (194, 195).